Slide 1: Exchange filing cover letter for Investor Presentation
28th January 2025 (1) BSE Ltd. (2) National Stock Exchange of India Ltd. Listing Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor Dalal Street Plot no. C/1, G Block Mumbai 400 001 Bandra Kurla Complex Scrip Code: 500087 Bandra (East), Mumbai - 400 051 Scrip Code: CIP
Slide 2: Investor Presentation Q3FY25
Investor Presentation Q3FY25 28-01-2025 1
Slide 3: Disclaimer
DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 4: Strong performance in focused markets; upward operating profitability trajectory
Strong performance1 in focused markets; upward operating profitability trajectory Revenue EBITDA PAT 16% (YoY) 50% (YoY) 8% INR 1,989 Cr INR 1,571 Cr Q3FY25 INR 7,073 Cr (YoY) 184 bps 617 bps 28.1% 22.2% of Revenue of Revenue Business Performance Snapshot Emerging Markets & One India North America S
Slide 5: Financial Performance – Q3FY25
Financial Performance1 – Q3FY25 Revenues INR 7,073 Cr EBITDA INR 1,989 Cr Revenue2 Break-up Q3FY25 (Consolidated) API, 2% Others, 1% Actuals vs Q3 FY24 Emerging Markets & (INR Cr) Europe, 12% Total Revenue from 7,073 8.1% Operations EBITDA 1,989 15.7% One Africa, One India, 14% 44% EBITDA % 28.1% 18
Slide 6: One India: Committed to drive long-term growth with a legacy of sustainability
One India1 : Committed to drive long-term growth with a legacy of sustainability One India revenue trend Q3FY23 INR 2,563 Cr CAGR Q3FY24 INR 2,859 Cr 11% Q3FY25 INR 3,146 Cr Branded Prescription Trade Generics Consumer Health ❖ Cipla maintained #2 market2 rank ❖ Business back on growth ❖ Delivered a
Slide 7: India Rx – Progressing on our journey backed by key therapies
India Rx – Progressing on our journey backed by key therapies Steady uptake in key therapies1 growth (%) Rank Largest pharma company by Volume (units) Respiratory 1.5 1st Slow industry 7.0 in market1 growth in Respiratory and Anti-infectives 3.4 4th Anti-infectives 5 brands added in the category of
Slide 8: One India: Accelerating innovative portfolio for Indian patients
One India : Accelerating innovative portfolio for Indian patients CLICK TO EDIT MASTER TITLE STYLE Afrezza Zemdri Cipenmet (Inhaled Insulin) (Plazomicin) (Novel anti-infective) ❑ Exclusive marketing and distribution ❑ Cipla strengthens fight against ❑ Cipla partners with Orchid Pharma to agreement w
Slide 9: 9M FY25: Global Consumer Wellness Franchise
9M FY25: Global Consumer Wellness Franchise One India : Revenue INR 1,132 Cr (9M FY25) 2 2 1 2 2 Pain relief Hydration Nicotine Replacement Skin infection Cold & cough INR 210+ Cr INR 145+ Cr INR 130+ Cr INR 95+ Cr INR 80+ Cr South Africa : Revenue ZAR 1,217 Mn (9M FY25) Respi OTC Cough, cold & flu
Slide 10: North America: Witnessed continuous traction in key differentiated assets
North America: Witnessed continuous traction in key differentiated assets $ Mn 250 229 230 226 237 226 222 195 204 179 155 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Key Business Highlights • Received various generic drug approvals, including Phytonadione injectable
Slide 11: ANDA & NDA Portfolio & Pipeline (As on 31st Dec 2024)
ANDA & NDA Portfolio & Pipeline (As on 31st Dec 2024) 8 66 9 3 16 7 87 2 2 53 19 11 Approved Tentatively Under Approval ANDAs & NDAs Approved ANDAs & NDAs ANDAs & NDAs 1 Cipla Ltd PEPFAR Invagen Partnered ANDAs/NDAs 170 34 79 283 Approved Tentatively Under Approval Total ANDAs & NDAs Approved ANDAs
Slide 12: One Africa: South Africa Private growing 2.5x faster than the market
One Africa1: South Africa Private growing 2.5x faster than the market ZAR Mn $ Mn One Africa Revenue SA Private Revenue trend 14 25 10 1,196 8 24 1,106 13 962 59 67 Q3FY24 Q3FY25 Q3FY23 Q3FY24 Q3FY25 SA Private SA Tender North Africa Others (SSA & CGA) Market Segment2 Rank Share Cipla Growth Market
Slide 13: Q3FY25: Emerging Markets & Europe and API
Q3FY25 : Emerging Markets & Europe and API Emerging Markets & Europe1 API $ Mn Revenue $ Mn Revenue 98 15 13 15% 20% 81 Q3FY24 Q3FY25 Q3FY24 Q3FY25 1. North Africa region is reclassified from Emerging Markets to One Africa. 12
Slide 14: Progressing on 2025 Environmental, Social & Governance goals
Progressing on 2025 Environmental, Social & Governance goals CLICK TO EDIT MASTER TITLE STYLE Progress on ESG Goals Cipla is included in: • DJSI World Index 2024 • DJSI Emerging Market Index 2024 • Achieved 1st place in India in the Drug and Pharma sector Cipla meets its Zero Waste to Land Fill goal
Slide 15: Consolidated Profit and Loss statement summary (Reported)
Consolidated Profit and Loss statement summary (Reported) INR Cr Particulars Q3 FY25 Q3 FY24 Revenue from sale of products 6,962 6,506 Other operating income 111 98 Income from operations 7,073 6,604 Material cost 2,264 2,220 Employee benefits expense 1,198 1,068 Other expenses 1,622 1,569 Total exp
Slide 16: Consolidated Balance Sheet (Reported)
Consolidated Balance Sheet (Reported) INR Cr Key Balance Sheet Items Dec-24 Sep-24 Equity 30,012 28,456 Total Debt 466 461 Inventory 5,562 5,573 Cash and Cash Equivalents* 9,413 8,412 Trade Receivables 5,858 5,588 Trade Payables 2,764 2,675 Net Tangible Assets 6,372 6,329 Goodwill and Intangibles 4,
Slide 17: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Diksha Maheshwari Investor.Relations@cipla.com For more information please visit www.cipla.com 16